
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT
- About


Goodrx Holdings Inc (GDRX)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: GDRX (1-star) is currently NOT-A-BUY. Pass it for now.
1 Year Target Price $5.37
1 Year Target Price $5.37
7 | Strong Buy |
1 | Buy |
7 | Hold |
1 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -65.98% | Avg. Invested days 21 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.23B USD | Price to earnings Ratio 39.33 | 1Y Target Price 5.37 |
Price to earnings Ratio 39.33 | 1Y Target Price 5.37 | ||
Volume (30-day avg) 16 | Beta 1.24 | 52 Weeks Range 3.31 - 8.80 | Updated Date 08/15/2025 |
52 Weeks Range 3.31 - 8.80 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.09 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-06 | When - | Estimate 0.1 | Actual 0.09 |
Profitability
Profit Margin 4.33% | Operating Margin (TTM) 13.2% |
Management Effectiveness
Return on Assets (TTM) 4.88% | Return on Equity (TTM) 5.27% |
Valuation
Trailing PE 39.33 | Forward PE 9.57 | Enterprise Value 1496192977 | Price to Sales(TTM) 1.54 |
Enterprise Value 1496192977 | Price to Sales(TTM) 1.54 | ||
Enterprise Value to Revenue 1.87 | Enterprise Value to EBITDA 8.4 | Shares Outstanding 98580704 | Shares Floating 82766063 |
Shares Outstanding 98580704 | Shares Floating 82766063 | ||
Percent Insiders 12.74 | Percent Institutions 66.39 |
Upturn AI SWOT
Goodrx Holdings Inc

Company Overview
History and Background
GoodRx was founded in 2011 by Doug Hirsch, Trevor Bezdek, and Scott Marlette. Initially focused on aggregating and comparing prescription drug prices, it has grown to offer telehealth services and other healthcare offerings. The company went public in September 2020.
Core Business Areas
- Prescription Transactions: Provides price comparisons and discount codes for prescription medications, generating revenue from pharmacy benefit managers (PBMs) and pharmacies when users fill prescriptions using GoodRx codes.
- Subscription Offerings: Offers subscription programs like GoodRx Gold and Kroger Rx Savings Club, providing deeper discounts and other benefits for a monthly fee.
- Pharma Manufacturer Solutions: Provides services to pharmaceutical manufacturers, including advertising, market research, and adherence programs.
- Telehealth: Offers telehealth services through its acquisition of HeyDoctor in 2019, connecting patients with healthcare providers for virtual consultations and prescriptions.
Leadership and Structure
Scott Wagner is the Interim CEO. The company has a traditional corporate structure with a board of directors and various executive leadership positions overseeing different functional areas.
Top Products and Market Share
Key Offerings
- Prescription Price Comparisons & Discounts: GoodRx's core product, allowing users to compare prices and access discounts on prescription drugs. Estimated to facilitate billions in prescription transactions annually. Competitors: SingleCare, Optum Perks, RxSaver.
- GoodRx Gold: Subscription service offering deeper discounts on medications. Number of subscribers undisclosed but a significant revenue driver. Competitors: Kroger Rx Savings Club, various PBM discount programs.
- Telehealth (GoodRx Care): Virtual healthcare services providing online consultations and prescriptions. Growing rapidly, with increasing user adoption. Competitors: Teladoc Health (TDOC), Amwell (AMWL).
Market Dynamics
Industry Overview
The healthcare industry is undergoing rapid digitalization and consumerization. Increasing drug prices and lack of price transparency are driving demand for solutions like GoodRx. Telehealth is experiencing significant growth due to convenience and accessibility.
Positioning
GoodRx is a leading player in the prescription drug price transparency and discount market. Its competitive advantages include brand recognition, a large user base, and strong relationships with pharmacies and PBMs.
Total Addressable Market (TAM)
The TAM for prescription drug discounts and telehealth is estimated to be in the tens of billions of dollars. GoodRx is well-positioned to capture a significant share of this market through its price transparency and accessibility.
Upturn SWOT Analysis
Strengths
- Strong Brand Recognition
- Large User Base
- Extensive Pharmacy Network
- Data-Driven Insights
- Proven Business Model
Weaknesses
- Reliance on PBM Relationships
- Potential for Regulatory Changes
- Competition from Established Players
- Dependence on Google Search Ranking
- Telehealth is very competitive
Opportunities
- Expansion into New Healthcare Services
- Partnerships with Healthcare Providers
- International Expansion
- Growth in Telehealth Adoption
- Increased Focus on Medication Adherence
Threats
- Increased Competition
- Changes in PBM Pricing Models
- Data Privacy Concerns
- Economic Downturn Impacting Healthcare Spending
- Regulatory Scrutiny
Competitors and Market Share
Key Competitors
- TDOC
- AMWL
- CVS
- WBA
Competitive Landscape
GoodRx faces competition from established players in the pharmacy and healthcare industries. Its competitive advantages include its strong brand recognition, large user base, and data-driven insights. Competitors are catching up in terms of user experience and breadth of service offerings.
Major Acquisitions
HeyDoctor
- Year: 2019
- Acquisition Price (USD millions):
- Strategic Rationale: Expanded GoodRx's telehealth capabilities.
Growth Trajectory and Initiatives
Historical Growth: GoodRx experienced rapid growth in its early years, driven by increasing demand for prescription drug discounts. Growth has slowed somewhat in recent years.
Future Projections: Analysts project continued revenue growth for GoodRx, driven by expansion into new healthcare services and increased adoption of telehealth. Earnings growth is expected to be impacted by investments in growth initiatives.
Recent Initiatives: Focus on expanding telehealth offerings, developing partnerships with healthcare providers, and improving medication adherence programs.
Summary
GoodRx is a prominent player in the prescription drug price comparison market with a strong brand and user base. While it faces increasing competition and regulatory uncertainties, its growth trajectory is supported by expanding telehealth services and strategic partnerships. The company has a solid financial position but must continue to innovate and adapt to maintain its competitive edge. The high net loss is a point of concern that the company must work on.
Peer Comparison
Sources and Disclaimers
Data Sources:
- GoodRx Investor Relations
- SEC Filings (10-K, 10-Q)
- Market Research Reports
- Analyst Estimates
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market conditions and company performance are subject to change. Actual results may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Goodrx Holdings Inc
Exchange NASDAQ | Headquaters Santa Monica, CA, United States | ||
IPO Launch date 2020-09-23 | President, CEO & Director Ms. Wendy Barnes | ||
Sector Healthcare | Industry Health Information Services | Full time employees 738 | Website https://www.goodrx.com |
Full time employees 738 | Website https://www.goodrx.com |
GoodRx Holdings, Inc., together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices. It also offers other healthcare products and services, including subscriptions and pharma manufacturer solutions, as well as telehealth services through the GoodRx Care platform. In addition, the company provides healthcare products and solution for dogs, cats, and other pets. It serves pharmacy benefit managers who manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was founded in 2011 and is headquartered in Santa Monica, California.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.